These data clearly indicatedthat a biologically significant interaction between selective COX-2 inhibitorsand PPAR-γ exists and that activation of PPAR-γ by these drugs may have detrimental, that istumor-promoting, effects on pancreatic cancer growth. This evidence concerns the gene PPARG and familial pancreatic carcinoma.